The Obstetrician & Gynaecologist 2008;10:4:211-216
doi: 10.1576/toag.10.4.211.27436
Copyright © 2008 by the Royal College of Obstetricians and Gynaecologists.
Endometrial hyperplasia
Julia E Palmer, MD MRCOG, Subspecialty Trainee, Gynaecological Oncology1,
Branko Perunovic, DM MRCPath FEBP, Consultant Histopathologist2 and
John A Tidy, BSc MD MRCOG, Consultant Gynaecological Oncologist3
1. Department of Gynaecological Oncology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK Email: palmer006{at}btinternet.com (corresponding author)
2. Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
3. Department of Gynaecological Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Key content:
- The most common presenting symptom of endometrial hyperplasia is abnormal uterine bleeding.
- In the UK, hysteroscopy remains the gold standard of investigations for abnormal uterine bleeding.
- The clinical importance of endometrial hyperplasia largely relates to the risk of progression to endometrial carcinoma.
- Progestin therapy is appropriate for most women with endometrial hyperplasia without atypia.
- The risk of endometrial carcinoma in the presence of cytological atypia deems hysterectomy an appropriate management.
Learning objectives:
- To learn about the aetiology and pathology of endometrial hyperplasia.
- To be able to select appropriate investigations and treatment.
Ethical issues:
- When is it appropriate to perform hysterectomy for the treatment of endometrial hyperplasias?
Please cite this article as: Palmer JE, Perunovic B, Tidy JA. Endometrial hyperplasia. The Obstetrician & Gynaecologist 2008;10:211–216.
Keywords abnormal uterine bleeding / endometrial carcinoma / endometrial intraepithelial neoplasia (EIN) / estrogen / progestogen
Copyright © 2008 by the Royal College of Obstetricians and Gynaecologists.